



ANTEO DIAGNOSTICS LIMITED (ASX: "ADO") OPERATIONAL UPDATE AND QUARTERLY REPORT

Key Points:

- **Cash at bank at the end of the first quarter 2010 was \$1.6 M.**
- **149,986,920 Listed 1.2 cent Options with a September 2010 expiry, having a value of \$1,799,843 remain unconverted at 30th April 2010.**
- **Bangs Laboratories are selling and actively promoting ProMag Bind-IT, their first product to incorporate Mix&Go.**
- **Internal testing is complete in a number projects for global entities and commercial discussions have commenced.**
- **International interest in Mix&Go technology grows confirming Anteo's strategic direction.**

The Board of Anteo Diagnostics Ltd now believes that the Company has sufficient funding to meet all of its requirements through until March 2011. There is confidence that the remaining 1.2 cent Options will be exercised before their expiry which, if it occurs, is expected to extend the runway to August 2011. These funding estimates are conservative and exclude royalty revenues that may be generated from Bangs Laboratories and any other revenues that result from anticipated additional commercial transactions.

Bangs Laboratories entered into a licensing agreement with Anteo in January 2010 and is now actively promoting and selling ProMag Bind-IT, its first product to incorporate Mix&Go. Bangs has expressed enthusiasm for the impact ProMag Bind-IT is having on its sales efforts. Testing for a second product by Anteo and Bangs is now well underway and a third product is identified for production.

We continue to satisfactorily progress all of our commercial interactions. A number of these have now completed their technical assessment and we are moving into commercial discussions.

Interest in Mix&Go continues to increase and has led to an additional ten (10) Materials Transfer Agreements and / or Confidentiality Agreements being negotiated in 2010.

This quarter has confirmed Anteo's strategic approach to exploit its capabilities in Immunodiagnostics with an eye to Point of Care testing and Molecular Diagnostics in the future. These two large global markets rival the size of our present focus market.

In summary, the Company is very satisfied with the commercial progress being made, the feedback it is receiving from those third parties testing Mix&Go in their own laboratories and the initial steps being taken into the next target areas.

Anteo Diagnostics Limited ABN 78 090 487 273

Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

Phone 07 3219 0085 Fax 07 3219 0553 Email contact@anteodx.com Web www.anteodx.com

For personal use only

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Name of entity

Anteo Diagnostics Limited

ACN or ARBN

75-070-028-625

Quarter ended
("current quarter")

31-Mar-10

Consolidated statement of cash flows

Cash flows related to operating activities		Current quarter \$A'000	Year to date (9 months) \$A'000
1.1	Receipts from customers and government grants	60	218
1.2	Payments for		
	(a) staff costs	(313)	(848)
	(b) advertising and marketing	(50)	(111)
	(c) research and development (excluding staff costs relating to R&D)	(91)	(285)
	(d) leased assets	-	-
	(e) other working capital	(259)	(741)
1.3	Dividends received	-	-
1.4	Interest and other items of a similar nature received	10	24
1.5	Interest and other costs of finance paid	-	(1)
1.6	Income taxes paid	-	-
Net operating cash flows		(643)	(1,744)

NOTES:

		Current quarter \$A'000	Year to date (9 months) \$A'000
1.8	Net operating cash flows (carried forward)	(643)	(1,744)
	Cash flows related to investing activities		
1.9	Payment for acquisition of:		
	(a) Businesses	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	(10)
	(e) other non-current assets	-	-
	Proceeds from disposal of:		
1.10	(a) Businesses	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	20
	(e) other non-current assets	-	-
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Adjustment for cash remaining in subsidiary entity at disposal	-	-
	Net investing cash flows	-	10
1.14	Total operating and investing cash flows	(643)	(1,734)
	Cash flows related to financing activities		
1.15	Proceeds from issues of shares, options, etc.	1,194	2,512
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	-	-
1.18	Repayment of borrowings	-	-
1.19	Dividends paid	-	-
1.20	Other:		
	Conversion of converting notes	-	-
	Interest paid on converting notes	-	-
	Capital raising costs	(2)	(117)
	Net financing cash flows	1,192	2,395
	Net increase (decrease) in cash held	549	661
1.21	Cash at beginning of quarter/year to date	1,065	953
1.22	Exchange rate adjustments to item 1.20	-	-
1.23	Cash at end of quarter	1,614	1,614

NOTES:

1.20

--	--

Payments to directors of the entity and associates of the directors
Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	226
1.25	Aggregate amount of loans to the parties included in item 1.11	NIL

1.26 Explanation necessary for an understanding of the transactions

--

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

NIL

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

NIL

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	NIL	NIL
3.2	Credit standby arrangements	NIL	NIL

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter \$A'000	Previous quarter \$A'000
4.1	Cash on hand and at bank	25	41
4.2	Deposits at call	1,589	1,024
4.3	Bank overdraft		-
4.4	Other - Funds held in trust re. Open Prospectus Offer		-
Total: cash at end of quarter (item 1.23)		1,614	1,065

Acquisitions and disposals of business entities

		Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1	Acquisition/disposal of subsidiary		
5.2	Place of incorporation or registration		
5.3	Consideration for acquisition or disposal		
5.4	Total net assets at date of acquisition/disposal		
5.5	Nature of business		

Compliance statement

1

This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act 2001 (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.

2

This statement **does** give a true and fair view of the matters disclosed.

Sign here:

Date: 30 April 2010

(Company Secretary)

Print name: **Shane Hartwig**

Notes

1 The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note

2 The definitions in, and provisions of, *AASB 1026: Statement of Cash Flows* apply to this report except for the paragraphs of the Standard set out below.

6.2 - reconciliation of cash flows arising from operating activities to operating profit or loss

9.2 - itemised disclosure relating to acquisitions

9.4 - itemised disclosure relating to disposals

12.1(a) - policy for classification of cash items

12.3 - disclosure of restrictions on use of cash

13.1 - comparative information

3

Accounting Standards. ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.